Amyloid Neuropathies

Amyloid Neuropathies are problems with the nerves in your body. They happen when a protein called AMYLOID builds up in the nerves. This can cause symptoms like numbness, weakness, and trouble with your hands, like carpal tunnel syndrome.

Condition

What people with Amyloid Neuropathies report

Every report comes from a Lived member, sent anonymously.

Have you tried Amvuttra (Vutrisiran) for Amyloid Neuropathies?

NameHow it went

About Amyloid Neuropathies

What It Is

Amyloid neuropathy is nerve damage caused by amyloid, an abnormal protein that misfolds, links into fibers and builds up in tissue. When these deposits collect in the peripheral nerves (the nerves that run from the spinal cord to the limbs and internal organs), they slowly disrupt sensation, strength and the automatic functions the body manages without conscious effort. The neuropathy usually begins in the feet with numbness, tingling, burning pain or a reduced ability to feel heat and pain, then gradually spreads upward. Weakness tends to come later. Many people also develop autonomic symptoms, meaning problems in the nerves that control blood pressure, digestion, the bladder and sexual function. These can show up as dizziness or fainting on standing, diarrhea or constipation (sometimes alternating), feeling full quickly, bladder problems, erectile dysfunction and unintended weight loss. Carpal tunnel syndrome, often in both wrists, is common and can appear years before other symptoms. Amyloid neuropathy is a feature of several forms of amyloidosis rather than a single disease. Nearly all cases come from two of them: hereditary transthyretin amyloidosis and light chain (AL) amyloidosis. Both can also affect the heart and other organs, and both are treatable, which is why recognizing the neuropathy and identifying its type matters.

Causes & Risk Factors

The cause depends on which protein is forming the amyloid. In hereditary transthyretin amyloidosis, the problem lies in transthyretin, a protein made mainly by the liver that carries thyroid hormone and vitamin A in the blood. An inherited variant in the transthyretin (TTR) gene changes the protein so that it comes apart more easily, and its pieces clump into amyloid. One inherited copy of the variant is enough to cause the condition, so it often runs in families, although not everyone who carries a variant develops symptoms. Symptoms can begin anywhere from about age 20 to 70. Some variants were first recognized in families from Portugal, Sweden and Japan, but the condition occurs worldwide, and a variant more common in people of African ancestry mainly affects the heart. In light chain amyloidosis, the source is a small, abnormal group of plasma cells (the immune cells that make antibodies) in the bone marrow. These cells produce excess antibody fragments called light chains, which misfold and deposit in nerves and organs. This form is acquired during life rather than inherited. Wild-type transthyretin amyloidosis occurs when normal transthyretin builds up with age, mainly in older adults. It most often affects the heart and the tissue around tendons, which is why carpal tunnel syndrome is common. Whether it also causes a wider neuropathy is still debated. Rarer inherited forms involve other proteins. None of these forms is caused by anything a person did.

How It's Diagnosed

Amyloid neuropathy is often diagnosed late, particularly when there is no known family history, because its early symptoms resemble far more common problems. It can be mistaken for diabetic neuropathy, nerve damage of unknown cause, lumbar spinal stenosis (narrowing in the lower spine) or chronic inflammatory demyelinating polyneuropathy (an immune-related nerve disorder). Features that raise suspicion include a neuropathy that keeps worsening, autonomic symptoms, carpal tunnel syndrome in both hands, unexplained weight loss, a thickened heart muscle and relatives with similar problems. Nerve conduction studies, which measure how well nerves carry electrical signals, show how much nerve damage there is. Specialists recommend that anyone with a progressive neuropathy of unclear cause also have blood and urine tests for an abnormal antibody protein, including a free light chain test, to look for light chain amyloidosis. Genetic testing of the TTR gene identifies the hereditary form. Confirming amyloid usually requires a tissue sample. A small sample of abdominal fat or skin is often taken first, and a nerve or other organ biopsy is sometimes needed. A special stain shows whether amyloid is present, and further testing identifies which protein it came from. Because deposits are patchy, a negative biopsy does not rule the condition out. Identifying the protein is essential, because hereditary transthyretin and light chain amyloidosis are treated in completely different ways. Once amyloid is confirmed, the heart is assessed with an electrocardiogram, an echocardiogram (heart ultrasound) and blood markers of heart strain, and sometimes with a nuclear bone-tracer heart scan that can detect transthyretin deposits. An eye examination and kidney tests are also part of a full assessment.

Treatment Options

Treatment depends on the type of amyloid, and it works best when started early, before nerve damage has built up. People who began treatment at a later stage have remained more disabled than those treated earlier. For hereditary transthyretin amyloidosis, the main treatments are gene-silencing medicines. They block the liver's production of transthyretin, so less of the protein is available to form new amyloid. In clinical trials these medicines halted the progression of neuropathy for most people and improved nerve function and quality of life compared with people given placebo in trials. Vutrisiran (Amvuttra) is an injection under the skin given by a health professional every three months, and is also approved for transthyretin amyloidosis affecting the heart. Eplontersen (Wainua) is a monthly injection under the skin that people can learn to give themselves with an autoinjector. Patisiran (Onpattro), the first of these medicines, is an intravenous infusion every three weeks that requires medicines beforehand to prevent infusion reactions. Because transthyretin carries vitamin A, all of these medicines lower vitamin A levels. People taking them are advised to take a vitamin A supplement at the recommended daily amount, but not higher doses. Another approach uses stabilizers, oral medicines that hold transthyretin together so it is less likely to break apart. Tafamidis is used for the neuropathy in Europe and elsewhere, but in the United States it is approved only for the heart form. Diflunisal, an older anti-inflammatory pain reliever, also slows nerve damage but can cause stomach bleeding, kidney problems and fluid retention that can worsen heart failure, which limits its use. Liver transplantation, once the main treatment, is now rarely needed. One-time gene-editing treatments are being tested in clinical trials. Light chain amyloidosis is treated by a hematologist (a blood disorder specialist) with therapy aimed at the abnormal plasma cells. For newly diagnosed people, a common approach combines daratumumab (Darzalex Faspro), an antibody that targets plasma cells, with bortezomib and cyclophosphamide, two cancer medicines, and dexamethasone, a steroid. This has improved survival considerably. Stem cell transplantation remains an option for some people but is no longer part of standard first treatment. Whatever the type, symptom care matters alongside these treatments: medicines for nerve pain, treatment for low blood pressure on standing and for digestive symptoms, and coordinated care from neurology, cardiology and other specialists.

What to Expect

Without treatment, hereditary transthyretin amyloid neuropathy steadily progresses over years, leading to serious disability, weight loss and heart problems that can shorten life. Modern treatments have changed that outlook substantially. Many people now remain stable for years. Treatment aims mainly to stop further damage, so how well someone functions often reflects how much damage occurred before it began, and the pace of the condition still differs between individuals and gene variants. Treatment is ongoing rather than a short course. Regular visits track nerve function, side effects and whether the disease is still progressing; a change of medicine may be considered if it is. Because the heart is often involved even when nerve symptoms dominate, regular cardiology checkups are recommended, and some people eventually need a pacemaker for heart rhythm problems. Deposits in the eye can cloud the clear gel that fills it, which can blur vision, or raise the pressure inside the eye (glaucoma). These deposits can continue to progress despite treatment, so periodic eye examinations are part of care, and any change in vision is worth reporting. These medicines are expensive, and arranging insurance coverage can take time. A hereditary diagnosis also affects relatives. Genetic counseling helps family members decide whether to be tested. People who carry a variant but have no symptoms are not treated preventively at present, but regular monitoring allows treatment to begin at the first signs of disease. For light chain amyloidosis, treatment is given in repeating cycles of injections and tablets, usually weekly at first and less often later, over many months. Free light chain blood tests, repeated during treatment, show how well the abnormal plasma cells are responding. The outlook depends on how well the plasma cell disorder responds and on which organs are involved, especially the heart.

When to Seek Help

See a doctor if numbness, tingling or burning in the feet keeps spreading or worsening, especially alongside dizziness on standing, ongoing diarrhea or constipation, unexplained weight loss, or carpal tunnel syndrome in both hands. A family history of amyloidosis or a known TTR variant is a reason to raise these symptoms early. If you are already being treated, tell your care team when symptoms progress or new ones appear. Trouble seeing at night or persistently dry eyes while taking a gene-silencing medicine should be reported so your eyes can be checked for low vitamin A. Contact your care team promptly about dizziness or nearly fainting when you stand up, new swelling in the legs, breathlessness that is gradually increasing, or a racing or irregular heartbeat, since these can signal heart involvement or a heart rhythm problem. Call 911 for fainting that comes without warning or during activity, fainting with a racing or pounding heartbeat or chest pain, or severe breathlessness at rest, because amyloid in the heart can cause dangerous rhythm problems.

Questions to Ask Your Doctor

  1. 1.Which type of amyloidosis is causing my neuropathy, and how was it confirmed?
  2. 2.How do the treatment options for my type compare in how they are given, how well they work and how they are monitored?
  3. 3.Has the amyloid affected my heart, eyes or kidneys, and how often should those be checked?
  4. 4.Should my relatives consider genetic counseling or testing, and what would a positive result mean for them?
  5. 5.Which of my symptoms, such as pain, dizziness or digestive problems, can be treated directly, and who should I see for each?

Last reviewed • Oct 2026

Educational content, not medical advice.